Avant Technologies designates Series B Convertible Preferred Stock for Wired4Health asset acquisition

AVAI BIO, INC.

Filed Certificate of Designation for 1M shares of Series B Convertible Preferred Stock.
Series B issued as partial consideration for acquiring Wired4Health assets; total consideration $2.2M.
Conversion price set at lesser of $1.00 per share or 30-day VWAP of common stock on OTC Markets.
Conversion subject to 4.99% beneficial ownership limitation and daily sales cap of 25% of total volume.
Preferred Stock has aggregate stated value of $1M; Secured Note of $1.2M also issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.